Literature DB >> 34532418

Erratum to delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.

.   

Abstract

[This corrects the article DOI: 10.21037/atm-20-6605.]. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Year:  2021        PMID： 34532418      PMCID： PMC8421940          DOI： 10.21037/atm-2021-22

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


In the article entitled “Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema” (1), there is an error of the funding information. The funding statement “This work was financially supported by the National Natural Science Foundation of China (8187020594)” should be corrected as “The project was supported by the National Natural Science Foundation of China (No. 81873530).” Click here to view the updated version of the article.
  1 in total

1.  Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.

Authors:  Bohan Li; Jiantao Yang; Raoping Wang; Jia Li; Xubo Li; Xiang Zhou; Shuai Qiu; Ricong Weng; Zichao Wu; Chunyuan Tang; Ping Li
Journal:  Ann Transl Med       Date:  2020-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.